Woori IO, an OSR Company, Signs NDA with Sinopharm for China Market and Global Multicenter Trials

Rhea-AI Summary

OSR Holdings (NASDAQ: OSRH) said subsidiary Woori IO signed a mutual NDA with Sinopharm on March 19, 2026 to share confidential information about Woori IO's noninvasive NIR continuous glucose monitoring technology.

The agreement enables evaluation of regulatory, clinical, and commercial pathways in China, notes Sinopharm's reported 2024 revenue of about USD 81 billion, and cites China market size (>140 million people with diabetes) and a projected device market >$12 billion by 2032. Discussions remain preliminary while Woori IO pursues potential global multicenter trials and other partner engagements.

Positive

• NDA signed with Sinopharm on March 19, 2026
• Access pathway to China regulatory and commercial evaluation
• China diabetes population >140 million supports market demand
• Market projection exceeding $12 billion by 2032

Negative

• Discussions are preliminary; no binding commercial deal yet
• No clinical trials initiated; development and approval remain pending

News Market Reaction – OSRH

+2.35%

10 alerts

+2.35% Session close to close

-16.1% Trough in 31 hr 36 min

$12.07M Market Cap

0.9x Rel. Volume

In the Mar 19 session, OSRH gained 2.35%, reflecting a moderate positive market reaction. Argus tracked a trough of -16.1% from its starting point during tracking. Our momentum scanner triggered 10 alerts that day, indicating notable trading interest and price volatility.

Data tracked by StockTitan Argus on the day of publication.

Market Context

This announcement highlights an NDA between Woori IO and Sinopharm to evaluate regulatory, clinical,...

Analysis

This announcement highlights an NDA between Woori IO and Sinopharm to evaluate regulatory, clinical, and commercial paths in China for noninvasive near-infrared glucose monitoring. The relationship connects OSR’s platform to a distributor with USD 81 billion in 2024 revenue in a diabetes market exceeding 140 million people. In recent months, OSRH advanced Woori IO’s acquisition, FDA-aligned commercialization plans, and strategic reviews, while also managing Nasdaq bid-price compliance—factors investors may monitor alongside future trial and partnership milestones.

Key Figures

Sinopharm 2024 revenue: USD 81 billion China diabetes population: more than 140 million people China diabetes device market: $12 billion +1 more

4 metrics

Sinopharm 2024 revenue USD 81 billion Reported 2024 revenue for Sinopharm Group

China diabetes population more than 140 million people Estimated people living with diabetes in China

China diabetes device market $12 billion Projected potential market size by 2032

Market horizon 2032 Projection year for China diabetes device market expansion

Historical Context

5 past events · Latest: Mar 05 (Positive)

Pattern 5 events

Date	Event	Sentiment	24h Move	Catalyst
Mar 05	Nasdaq extension, strategy	Positive	+14.7%	Nasdaq bid-price cure extension and reaffirmed licensing and device merger strategy.
Feb 02	CEO strategic update	Positive	-4.3%	CEO statement on Nasdaq timing, VXM01 licensing and device merger plans.
Jan 27	Woori IO acquisition	Positive	-3.9%	Completion of Woori IO acquisition and review of combining device subsidiaries.
Jan 22	FDA clarification, launch	Positive	+10.2%	FDA stance on non-medical wearables enabling phased commercialization strategy.
Jan 16	Vaximm CSO hire	Positive	-4.4%	Appointment of new CSO to advance the VXM01 oral immunotherapy platform.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

Recent news often produced mixed reactions, with some positive catalysts sold off and others drawing double-digit gains.

Recent Company History

Over the past six months, OSR Holdings navigated Nasdaq minimum bid-price issues while advancing strategic initiatives. A January 2026 acquisition made Woori IO a consolidated subsidiary, anchoring its noninvasive glucose monitoring platform. Subsequent news highlighted FDA clarification enabling a two-phase commercialization path and a potential merger of device subsidiaries. Nasdaq granted a 180-day extension to August 31, 2026 for bid-price compliance, and Vaximm governance and leadership updates supported pipeline progress. Today’s Sinopharm NDA fits into this ongoing effort to expand Woori IO’s global commercialization footprint.

Key Terms

regulation fd, non-disclosure agreement, near-infrared (nir), continuous glucose monitoring, +1 more

5 terms

regulation fd regulatory

"This announcement is being made in accordance with Regulation FD to ensure broad..."

Regulation FD is a rule that prevents company insiders, like executives, from sharing important information with some people before others get it. It matters because it helps ensure all investors have equal access to key news, making the stock market fairer and reducing chances of insider trading.

non-disclosure agreement regulatory

"has entered into a mutual non-disclosure agreement ("NDA") with Sinopharm Group..."

A non-disclosure agreement is a legal contract that prevents one or more parties from sharing confidential information with others. It matters to investors because it helps protect sensitive business details, ensuring that important information remains private and cannot be used against the company or its partners. Think of it as a formal promise to keep certain information secret, similar to a trust between friends about a surprise gift.

near-infrared (nir) medical

"noninvasive near-infrared (NIR) glucose monitoring technology, allowing both parties..."

Near-infrared (NIR) is the band of light just beyond the visible red that people can’t see but can be detected by special sensors; think of it like twilight light that a camera tuned differently can pick up. It matters to investors because NIR is used in medical imaging, wearable health monitors, industrial sensors and remote sensing—areas where better detection can create product advantages, revenue growth and regulatory considerations for companies using the technology.

continuous glucose monitoring medical

"offering noninvasive, needle-free continuous glucose monitoring without the pain..."

Continuous glucose monitoring is a system that tracks blood sugar levels in real-time throughout the day and night. It provides constant updates, similar to a car's dashboard showing speed and fuel level at all times. For investors, advancements in this technology can signal progress in health monitoring devices, which may influence the growth and valuation of companies in the healthcare sector.

multicenter trials medical

"for China Market and Global Multicenter Trials"

Research studies that run the same medical test or treatment at multiple hospitals or clinics at the same time, like trying a recipe in several different kitchens to see if it works broadly. For investors, multicenter trials matter because they usually involve larger patient groups and more varied conditions, which makes results more reliable, lowers the chance of surprising failures, and influences regulatory approval and commercial prospects.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

BELLEVUE, Wash., March 19, 2026 /PRNewswire/ -- OSR Holdings, Inc. (NASDAQ: OSRH), a healthcare-focused holding company advancing innovative medical technologies, today announced that its subsidiary, Woori IO Co., Ltd. ("Woori IO"), has entered into a mutual non-disclosure agreement ("NDA") with Sinopharm Group Beijing Huahong ("Sinopharm"), the Beijing-based unit of Sinopharm Group and major state-owned healthcare and pharmaceutical distribution enterprise of China. This announcement is being made in accordance with Regulation FD to ensure broad, non-exclusionary public dissemination of this information.

The NDA establishes a formal framework for Woori IO and Sinopharm to exchange confidential information relating to Woori IO's noninvasive near-infrared (NIR) glucose monitoring technology, allowing both parties to evaluate potential regulatory, clinical, and commercial pathways in China. Sinopharm Group, with reported 2024 revenue of approximately USD 81 billion, is generally considered China's largest pharmaceutical and medical device distributor with the most extensive nationwide network.

China represents one of the world's largest and fastest-growing diabetes markets, with more than 140 million people estimated to be living with the disease and rising demand for convenient glucose monitoring solutions. China's diabetes device market is projected to expand significantly over the next decade, potentially exceeding $12 billion by 2032, according to a report by Research and Markets, as adoption of advanced glucose monitoring technologies accelerates. Woori IO's proprietary NIR optical sensing technology addresses this demand directly, offering noninvasive, needle-free continuous glucose monitoring without the pain and adoption barriers of conventional invasive methods.

"China is a highly compelling market, given its large and growing diabetes population and increasing adoption of advanced glucose monitoring technologies," said Peter Hwang, CEO of OSR Holdings. "Our engagement with Sinopharm reflects the strategic importance of the China market and the potential role that established national distribution platforms may play in enabling future commercialization. While still at an early stage, this engagement underscores the broader global interest in Woori IO's noninvasive glucose monitoring platform."

Woori IO has received additional interest from healthcare organizations, pharmaceutical companies, and distribution partners across multiple regions, highlighting growing recognition of its noninvasive glucose monitoring platform and strong demand for more accessible, patient-friendly solutions. "Our NDA with Sinopharm allows us to begin evaluating potential regulatory and commercial pathways in China while continuing discussions with partners in other regions," said Sunkie Park, CEO of Woori IO. "These interactions could help shape future clinical development programs, including potential global multicenter trials."

While discussions remain preliminary, OSR Holdings intends to actively pursue strategic partnerships across major international markets as it advances development, regulatory strategy, and potential commercialization pathways for this next-generation glucose monitoring technology, which could represent a transformational step forward in improving accessibility and convenience in diabetes care globally.

About OSR Holdings, Inc.

OSR Holdings, Inc. (NASDAQ:OSRH) is a global healthcare holding company dedicated to advancing biomedical innovation approaches to health and wellness. Through its subsidiaries, OSRH is engaged in immuno-oncology, regenerative biologics, and medical device technologies. Its vision is to build a portfolio of breakthrough healthcare solutions to improve global health outcomes. Learn more at www.OSR-Holdings.com.

About Woori IO Co., Ltd.

Woori IO is a South Korea-based medical device company developing noninvasive biosensing technologies for glucose monitoring and beyond. Its proprietary NIRS-based system enables accurate, pain-free glucose tracking and is designed for integration into wearables. The company has been recognized by a leading global consumer electronics company's startup program for its innovation in NIGM technology. Learn more at www.woori.io.

Contact:

Media & Investor Contacts
OSR Holdings, Inc.
Investor Relations
ir@osr-holdings.com

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements include statements regarding potential collaboration opportunities, anticipated commercialization pathways, regulatory strategy, global market demand for noninvasive CGM technology, and future business prospects. These statements are based on current expectations and assumptions and involve risks and uncertainties that could cause actual results to differ materially from those expressed or implied. Factors that may affect future results include, but are not limited to, the ability to enter into definitive agreements with prospective partners, regulatory approvals, product development outcomes, market acceptance, competitive developments, capital market conditions, and other risks described in OSR Holdings' filings with the U.S. Securities and Exchange Commission. OSR Holdings undertakes no obligation to update forward-looking statements except as required by law.

View original content to download multimedia:https://www.prnewswire.com/news-releases/woori-io-an-osr-company-signs-nda-with-sinopharm-for-china-market-and-global-multicenter-trials-302718811.html

SOURCE OSR Holdings

FAQ

What did OSR Holdings (OSRH) announce about Woori IO and Sinopharm on March 19, 2026?

They signed a mutual NDA to exchange confidential information about Woori IO's noninvasive NIR glucose monitoring technology. According to the company, the NDA allows evaluation of regulatory, clinical, and commercial pathways in China while discussions remain at an early stage.

How could the Woori IO NDA with Sinopharm affect OSRH's China commercialization plans?

The NDA enables formal evaluation of regulatory and commercial options in China. According to the company, this framework permits discussions on potential registration routes, distribution partnerships, and shaping clinical development for future market entry.

Does the OSRH announcement confirm clinical trials for Woori IO in China or globally?

No definitive trials were announced; the company said discussions could inform potential global multicenter trials. According to the company, clinical development pathways remain under evaluation and no trial start dates were provided.

What China market figures did OSR Holdings cite in the March 19, 2026 announcement?

OSR cited more than 140 million people living with diabetes in China and a projected device market potentially exceeding $12 billion by 2032. According to the company, these figures highlight strong demand for noninvasive glucose monitoring.

Is the NDA with Sinopharm a binding commercial agreement for OSRH (Woori IO)?

No, the NDA is a mutual confidentiality framework and not a commercial contract. According to the company, it permits information exchange to evaluate regulatory and commercial pathways but does not commit either party to transactions.

What are the near-term next steps OSR Holdings (OSRH) described after the Sinopharm NDA?

OSR plans to evaluate regulatory strategy and pursue strategic partnerships across international markets. According to the company, these engagements may shape clinical development and potential commercialization pathways while discussions continue.